Association of Plasma Aß40 Peptides, But Not Aß42, with Coronary Artery Disease and Diabetes Mellitus.

ABSTRACT

BACKGROUND/OBJECTIVE: Plasma levels of amyloid-beta (Aß) 1-40 peptide have been proposed to be associated with cardiovascular mortality in patients with coronary artery disease (CAD). Therefore, we aimed to investigate the association of plasma Aß levels with CAD, cardiovascular risk factors (CVRF), and APOE genotype in non-demented elderly individuals. METHODS: Plasma Aß1 - 40 and Aß1 - 42 levels of 526 individuals (mean age of 63.0±7.3 years) were quantified with the INNO-BIA plasma Aß forms assay based on multiplextrademark technique. APOE genotype was determined with an established protocol. Presence of CAD and CVRFs were ascertained using a questionnaire and/or medical records. RESULTS: Plasma Aß1 - 40 levels were significantly higher in individuals with CAD (p = 0.043) and, independently, in individuals with diabetes mellitus (DM) type 2 (p = 0.001) while accounting for age- and gender-effects. Plasma Aß1 - 42 levels were higher in APOEɛ4 carriers (p = 0.004), but were neither relevantly associated with CAD nor with any CVRF. Plasma Aß1 - 40 showed no association with APOE genotype. DISCUSSION: Our findings argue for an association of circulating plasma Aß1 - 40 peptides with incident CAD and DM. Further investigations are needed to entangle the role of Aß1 - 40 role in the pathophysiology of cardiovascular disease independent of its known role in Alzheimer's disease.